Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -1.94% and Operating profit at -37.12% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 8.70% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -1.94% and Operating profit at -37.12% over the last 5 years
3
The company has declared Negative results for the last 4 consecutive quarters
4
Risky -
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,650 Million (Large Cap)
NA (Loss Making)
NA
0.00%
1.17
-8.22%
3.21
Revenue and Profits:
Net Sales:
2,789 Million
(Quarterly Results - Jun 2025)
Net Profit:
67 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.7%
0%
-13.7%
6 Months
-10.76%
0%
-10.76%
1 Year
-27.75%
0%
-27.75%
2 Years
-62.48%
0%
-62.48%
3 Years
-39.87%
0%
-39.87%
4 Years
22.31%
0%
22.31%
5 Years
28.66%
0%
28.66%
Chongqing Taiji Industry (Group) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.94%
EBIT Growth (5y)
-37.12%
EBIT to Interest (avg)
2.30
Debt to EBITDA (avg)
9.28
Net Debt to Equity (avg)
1.36
Sales to Capital Employed (avg)
1.64
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.73%
ROE (avg)
8.70%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.21
EV to EBIT
1591.08
EV to EBITDA
44.67
EV to Capital Employed
2.02
EV to Sales
1.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.13%
ROE (Latest)
-8.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2,788.80
2,803.30
-0.52%
Operating Profit (PBDIT) excl Other Income
82.60
247.50
-66.63%
Interest
34.40
32.60
5.52%
Exceptional Items
-1.20
-9.80
87.76%
Consolidate Net Profit
67.30
75.10
-10.39%
Operating Profit Margin (Excl OI)
29.60%
48.30%
-1.87%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -0.52% vs 46.71% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -10.39% vs 115.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
12,228.00
15,433.40
-20.77%
Operating Profit (PBDIT) excl Other Income
888.80
1,621.30
-45.18%
Interest
142.80
151.40
-5.68%
Exceptional Items
-14.20
-84.90
83.27%
Consolidate Net Profit
51.30
853.50
-93.99%
Operating Profit Margin (Excl OI)
36.20%
76.00%
-3.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -20.77% vs 10.49% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -93.99% vs 146.68% in Dec 2023
About Chongqing Taiji Industry (Group) Co., Ltd. 
Chongqing Taiji Industry (Group) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






